Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2+ Metastatic Breast Cancer (MBC)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT00567190
What this trial is testing

Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Genentech, Inc. 808
Testing effectiveness (Phase 2)Looking for participantsNCT07441889
What this trial is testing

HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)

Who this might be right for
Breast CancerProstate Cancer
University of Virginia 23
Not applicableLooking for participantsNCT06762483
What this trial is testing

Integrated Testing Strategy for Simultaneous Detection of ESR-1 and gBRCA Mutations Via Liquid Biopsy in HR+/HER2- Metastatic Breast Cancer (mBC) Patients,

Who this might be right for
Breast Cancer, Metastatic
European Institute of Oncology 80
Not applicableUnknownNCT04758416
What this trial is testing

Study on the Value of Non-invasive Dual-Pet Information in Subtype of Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 50
Testing effectiveness (Phase 2)Study completedNCT04240106
What this trial is testing

Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)

Who this might be right for
Breast CancerBreast Cancer Metastatic
MedSIR 14
Not applicableStudy completedNCT01291667
What this trial is testing

Study for HER2-Overexpressed MBC Patients Treated by Cipterbin® Plus vinorelbinE

Who this might be right for
Progress-free SurvivalOverall Response RateAdverse Events
Shanghai CP Guojian Pharmaceutical Co., Ltd. 330
Testing effectiveness (Phase 2)Ended earlyNCT03858972
What this trial is testing

Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC

Who this might be right for
Breast Cancer
Odonate Therapeutics, Inc. 152
Testing effectiveness (Phase 2)Study completedNCT02536339
What this trial is testing

Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy

Who this might be right for
Metastatic Breast Cancer
Genentech, Inc. 40
Testing effectiveness (Phase 2)Study completedNCT00679211
What this trial is testing

Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Genentech, Inc. 110
Testing effectiveness (Phase 2)Study completedNCT00825734
What this trial is testing

Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
SCRI Development Innovations, LLC 83
Testing effectiveness (Phase 2)Study completedNCT04603183
What this trial is testing

ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL

Who this might be right for
Breast Cancer Metastatic
MedSIR 162
Testing effectiveness (Phase 2)Study completedNCT01439191
What this trial is testing

Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Shanghai CP Guojian Pharmaceutical Co., Ltd. 109
Large-scale testing (Phase 3)Ended earlyNCT04869943
What this trial is testing

Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Veru Inc. 52
Not applicableStudy completedNCT04460911
What this trial is testing

Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.

Who this might be right for
Breast Cancer
Pfizer 317
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07619365
What this trial is testing

Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer

Who this might be right for
Breast CancerAdvanced Breast CancerMetastatic Breast Cancer
Washington University School of Medicine 60
Testing effectiveness (Phase 2)UnknownNCT03876587
What this trial is testing

Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC

Who this might be right for
Metastatic Breast Cancer
Zhejiang Cancer Hospital 79
Testing effectiveness (Phase 2)Study completedNCT00943670
What this trial is testing

Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

Who this might be right for
Metastatic Breast Cancer
Genentech, Inc. 51
Early research (Phase 1)Active Not RecruitingNCT05654532
What this trial is testing

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Accutar Biotechnology Inc 100
Large-scale testing (Phase 3)Study completedNCT01808573
What this trial is testing

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting

Who this might be right for
HER2+ Metastatic Breast Cancer (MBC)
Puma Biotechnology, Inc. 621
Early research (Phase 1)Study completedNCT02649686
What this trial is testing

Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab

Who this might be right for
Metastatic Breast Cancer
Canadian Cancer Trials Group 15
Next Page